Literature DB >> 22740283

Comparing alumina-reduced and conventional surface grit-blasted acetabular cups in primary THA: early results from a randomised clinical trial.

Ronald Veldstra1, Annemarie van Dongen, Eric C Kraaneveld.   

Abstract

Alumina grit-blasted implants have been widely used in cementless total hip arthroplasty (THA). However, alumina particles can become embedded in the implant surface, leading to deposition in periprosthetic tissues and implant wear. We hypothesised that the alumina-reduced surface BICON-PLUS NT acetabular cup would improve implant fixation and clinical outcomes over the conventional surface BICON-PLUS cup. In a randomised controlled, double-blind study, patients with primary or secondary osteoarthritis requiring primary arthroplasty were randomly assigned to THA with either the BICON-PLUS or BICON-PLUS NT cup. All cups were combined with the SL-PLUS stem. In addition to clinical and radiographic assessments, dual-energy X-absorptiometry (DEXA) was performed preoperatively and at regular intervals during a planned 2-year follow-up period to measure bone mineral density as a marker of implant fixation. At 1 year, there were no differences in bone mineral density, or in clinical or radiographic outcomes between the BICON-PLUS and BICON-PLUS NT groups were identified, leading to early termination of the study. Both groups showed excellent clinical improvement and there were few complications. Both the alumina-reduced and conventional surface acetabular cups can be used with confidence in primary THA for osteoarthritis, although longer-term studies are required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740283     DOI: 10.5301/HIP.2012.9244

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  1 in total

1.  Peri-acetabular bone remodelling after uncemented total hip arthroplasty with monoblock press-fit cups: an observational study.

Authors:  Conrad Anderl; Georg Mattiassich; Reinhold Ortmaier; Martin Steinmair; Josef Hochreiter
Journal:  BMC Musculoskelet Disord       Date:  2020-10-06       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.